兰地洛尔治疗感染性休克重症监护患者:LANDI-SEP随机对照试验方案
LANDI-SEP是一项IV期、多中心、前瞻性、随机、开放标签、对照研究,计划纳入200例液体复苏后仍存在心动过速(心率≥95次/分)的感染性休克患者,随机接受标准治疗联合兰地洛尔持续输注(目标心率80-94次/分)或单纯标准治疗,主要评价24小时内的心率应答与维持及不增加血管升压药需求。
要点
- 针对感染性休克液体复苏后持续心动过速(心率≥95次/分)患者。
- 兰地洛尔为高β1选择性、超短效β受体阻滞剂,持续输注目标心率80-94次/分。
- 主要终点为启动治疗后24小时内心率应答与维持且不增加血管升压药需求。
核心结论
- 本研究旨在验证兰地洛尔控制感染性休克患者心动过速的有效性且不增加血管升压药需求。
研究设计与样本
- IV期、多中心、前瞻性、随机、开放标签、对照研究,计划纳入200例感染性休克伴心动过速患者。
- 感染性休克依据第三次国际共识定义(Sepsis-3)诊断,心动过速定义为心率≥95次/分且经24-36小时血流动力学优化后仍存在。
- 患者按1:1随机接受标准治疗(依据2016年拯救脓毒症运动指南)联合兰地洛尔持续输注或单纯标准治疗。
关键数值与推荐
- 兰地洛尔组目标心率为80-94次/分。
- 主要终点为启动治疗后24小时内心率应答(80-94次/分)、其维持及不增加血管升压药需求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with septic shock, the presence of an elevated heart rate (HR) after fluid resuscitation marks a subgroup of patients with a particularly poor prognosis. Several studies have shown that HR control in this population is safe and can potentially improve outcomes. However, all were conducted in a single-center setting. The aim of this multicenter study is to demonstrate that administration of the highly beta1-selective and ultrashort-acting beta blocker landiolol in patients with septic shock and persistent tachycardia (HR ≥ 95 beats per minute [bpm]) is effective in reducing and maintaining HR without increasing vasopressor requirements. METHODS: A phase IV, multicenter, prospective, randomized, open-label, controlled study is being conducted. The study will enroll a total of 200 patients with septic shock as defined by The Third International Consensus Definitions for Sepsis and Septic Shock criteria and tachycardia (HR ≥ 95 bpm) despite a hemodynamic optimization period of 24-36 h. Patients are randomized (1:1) to receive either standard treatment (according to the Surviving Sepsis Campaign Guidelines 2016) and continuous landiolol infusion to reach a target HR of 80-94 bpm or standard treatment alone. The primary endpoint is HR response (HR 80-94 bpm), the maintenance thereof, and the absence of increased vasopressor requirements during the first 24 h after initiating treatment. DISCUSSION: Despite recent studies, the role of beta blockers in the treatment of patients with septic shock remains unclear. This study will investigate whether HR control using landiolol is safe, feasible, and effective, and further enhance the understanding of beta blockade in patients with septic shock. TRIAL REGISTRATION: EU Clinical Trials Register; EudraCT, 2017-002138-22 . Registered on 8 August 2017.
引用
- Unger M, Morelli A, Singer M, et al. Landiolol in patients with septic shock resident in an intensive care unit (LANDI-SEP): study protocol for a randomized controlled trial. Trials. 2018. PMID: 30454042. doi:10.1186/s13063-018-3024-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。